Ibrutinib Reverses IL-6-Induced Osimertinib Resistance through Inhibition of Laminin α5/FAK Signaling

By
Justin.choi
-
0
10
The authors showed that clinically, plasma interleukin-6 (IL-6) level predicted osimertinib efficacy in epidermal growth factor receptor mutant NSCLC patients.
[Communications Biology]

Sorry, but the selected Zotpress account can't be found.

Full Article